Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'adverse events'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents / Samuele CORTESE in Journal of Child Psychology and Psychiatry, 54-3 (March 2013)
[article]
Titre : Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents Type de document : Texte imprimé et/ou numérique Auteurs : Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur Article en page(s) : p.227-246 Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246[article] Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents [Texte imprimé et/ou numérique] / Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur . - p.227-246.
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246
Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191 The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability / P. BALLESTER in Autism Research, 15-1 (January 2022)
[article]
Titre : The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability Type de document : Texte imprimé et/ou numérique Auteurs : P. BALLESTER, Auteur ; C. ESPADAS, Auteur ; A. C. LONDOÑO, Auteur ; S. ALMENARA, Auteur ; Víctor AGUILAR, Auteur ; C. BELDA, Auteur ; E. PÉREZ, Auteur ; J. MURIEL, Auteur ; A. M. PEIRO, Auteur Article en page(s) : p.192-202 Langues : Anglais (eng) Mots-clés : Adult Autism Spectrum Disorder/drug therapy Humans Intellectual Disability Male Prospective Studies Psychotropic Drugs/therapeutic use Retrospective Studies adverse events autism spectrum disorder pharmacovigilance Index. décimale : PER Périodiques Résumé : Adults with autism spectrum disorder (ASD) and associated intellectual disability (ID) take a high number of different psychotropic drugs simultaneously. Nowadays, little is known about this multidrug pattern efficacy and safety. The present study has endeavored to fill this gap creating a local pharmacovigilance system. A 36-month, retrospective and prospective, observational, and multicenter pharmacovigilance study was carried out in adults with ASD and ID (n = 83). Information regarding ongoing medications (polypharmacy: taking simultaneously >4 drugs; safety profile: adverse events' number, adverse drug reactions' number, and affected system; and observed-to-expected [O/E] ratio using the summary of product characteristics), and current diagnoses were recorded. A median of four ongoing medications per participant was registered, half of the sample was under polypharmacy regimen. Regarding all ongoing medications, 50% were antipsychotic drugs, and 47% of participants had >1 antipsychotic prescribed. In contrast, only 64 adverse events were identified from electronic health records, mostly due to risperidone. Half of them were related either to nervous or metabolic systems, and almost a third were not previously described in the corresponding drug summary of products characteristics. Extrapyramidalism, gynecomastia, hypercholesterolemia, and urinary retention were some AEs that occurred more frequently than expected (O/E ratio?>?6 times) according to our data. The highest O/E ratio scores (>120 times) were for hypercholesterolemia and rhabdomyolysis caused by valproic acid. According to the number of adverse events and adverse drug reactions reported in electronic health records locally and nationally by clinicians, we need to increase awareness about medications safety. LAY SUMMARY: A 36-month study in adults with autism, ID, and polypharmacy (>4 drugs) was done to investigate drug safety on everyone. A median of four medications per person was registered, half were antipsychotic drugs, and 47% of participants had >1 antipsychotic medication simultaneously. Only 64 adverse events were identified from electronic health records, mostly due to risperidone. Half of them were related to nervous or metabolic systems and a third were not previously described in the drug information sheet. En ligne : http://dx.doi.org/10.1002/aur.2624 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450
in Autism Research > 15-1 (January 2022) . - p.192-202[article] The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability [Texte imprimé et/ou numérique] / P. BALLESTER, Auteur ; C. ESPADAS, Auteur ; A. C. LONDOÑO, Auteur ; S. ALMENARA, Auteur ; Víctor AGUILAR, Auteur ; C. BELDA, Auteur ; E. PÉREZ, Auteur ; J. MURIEL, Auteur ; A. M. PEIRO, Auteur . - p.192-202.
Langues : Anglais (eng)
in Autism Research > 15-1 (January 2022) . - p.192-202
Mots-clés : Adult Autism Spectrum Disorder/drug therapy Humans Intellectual Disability Male Prospective Studies Psychotropic Drugs/therapeutic use Retrospective Studies adverse events autism spectrum disorder pharmacovigilance Index. décimale : PER Périodiques Résumé : Adults with autism spectrum disorder (ASD) and associated intellectual disability (ID) take a high number of different psychotropic drugs simultaneously. Nowadays, little is known about this multidrug pattern efficacy and safety. The present study has endeavored to fill this gap creating a local pharmacovigilance system. A 36-month, retrospective and prospective, observational, and multicenter pharmacovigilance study was carried out in adults with ASD and ID (n = 83). Information regarding ongoing medications (polypharmacy: taking simultaneously >4 drugs; safety profile: adverse events' number, adverse drug reactions' number, and affected system; and observed-to-expected [O/E] ratio using the summary of product characteristics), and current diagnoses were recorded. A median of four ongoing medications per participant was registered, half of the sample was under polypharmacy regimen. Regarding all ongoing medications, 50% were antipsychotic drugs, and 47% of participants had >1 antipsychotic prescribed. In contrast, only 64 adverse events were identified from electronic health records, mostly due to risperidone. Half of them were related either to nervous or metabolic systems, and almost a third were not previously described in the corresponding drug summary of products characteristics. Extrapyramidalism, gynecomastia, hypercholesterolemia, and urinary retention were some AEs that occurred more frequently than expected (O/E ratio?>?6 times) according to our data. The highest O/E ratio scores (>120 times) were for hypercholesterolemia and rhabdomyolysis caused by valproic acid. According to the number of adverse events and adverse drug reactions reported in electronic health records locally and nationally by clinicians, we need to increase awareness about medications safety. LAY SUMMARY: A 36-month study in adults with autism, ID, and polypharmacy (>4 drugs) was done to investigate drug safety on everyone. A median of four medications per person was registered, half were antipsychotic drugs, and 47% of participants had >1 antipsychotic medication simultaneously. Only 64 adverse events were identified from electronic health records, mostly due to risperidone. Half of them were related to nervous or metabolic systems and a third were not previously described in the drug information sheet. En ligne : http://dx.doi.org/10.1002/aur.2624 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450 Adverse event reporting in intervention research for young autistic children / Kristen BOTTEMA-BEUTEL in Autism, 25-2 (February 2021)
[article]
Titre : Adverse event reporting in intervention research for young autistic children Type de document : Texte imprimé et/ou numérique Auteurs : Kristen BOTTEMA-BEUTEL, Auteur ; Shannon CROWLEY, Auteur ; Micheal SANDBANK, Auteur ; Tiffany G. WOYNAROSKI, Auteur Article en page(s) : p.322-335 Langues : Anglais (eng) Mots-clés : adverse effects adverse events autism harms intervention young children Index. décimale : PER Périodiques Résumé : In this study, we looked at published research on interventions for young autistic children that did not involve administering medication. We were interested in determining how often studies reported on whether adverse events (i.e. physical or psychological distress to the participants) or adverse effects (i.e. adverse events that are thought to be caused by the intervention) had occurred. We found that of the 150 reports we examined, only 11 mentioned adverse events. One of these studies reported adverse events occurred, and three reported that adverse effects occurred. We also reviewed the studies to examine the reasons that were given to explain why any participants dropped out of the intervention (termed "withdrawal"), to determine if any of these reasons could be considered adverse events or adverse effects. Fifty-four studies described reasons for withdrawal, and 10 of these studies had reasons that could be categorized as an adverse event, 8 studies had reasons that could be categorized as an adverse effect, and an additional 12 studies had reasons that were too vaguely described to determine whether they were adverse events or not. We recommend that autism intervention researchers develop more systematic methods of looking for and reporting adverse events and effects, so that professionals and families can be better informed when choosing to enroll their autistic children in interventions. En ligne : http://dx.doi.org/10.1177/1362361320965331 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=441
in Autism > 25-2 (February 2021) . - p.322-335[article] Adverse event reporting in intervention research for young autistic children [Texte imprimé et/ou numérique] / Kristen BOTTEMA-BEUTEL, Auteur ; Shannon CROWLEY, Auteur ; Micheal SANDBANK, Auteur ; Tiffany G. WOYNAROSKI, Auteur . - p.322-335.
Langues : Anglais (eng)
in Autism > 25-2 (February 2021) . - p.322-335
Mots-clés : adverse effects adverse events autism harms intervention young children Index. décimale : PER Périodiques Résumé : In this study, we looked at published research on interventions for young autistic children that did not involve administering medication. We were interested in determining how often studies reported on whether adverse events (i.e. physical or psychological distress to the participants) or adverse effects (i.e. adverse events that are thought to be caused by the intervention) had occurred. We found that of the 150 reports we examined, only 11 mentioned adverse events. One of these studies reported adverse events occurred, and three reported that adverse effects occurred. We also reviewed the studies to examine the reasons that were given to explain why any participants dropped out of the intervention (termed "withdrawal"), to determine if any of these reasons could be considered adverse events or adverse effects. Fifty-four studies described reasons for withdrawal, and 10 of these studies had reasons that could be categorized as an adverse event, 8 studies had reasons that could be categorized as an adverse effect, and an additional 12 studies had reasons that were too vaguely described to determine whether they were adverse events or not. We recommend that autism intervention researchers develop more systematic methods of looking for and reporting adverse events and effects, so that professionals and families can be better informed when choosing to enroll their autistic children in interventions. En ligne : http://dx.doi.org/10.1177/1362361320965331 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=441